XML 70 R51.htm IDEA: XBRL DOCUMENT v3.4.0.3
(LOSS) EARNINGS PER SHARE (Tables)
 12 Months Ended
Dec. 31, 2015
Earnings Per Share [Abstract]  
Schedule of calculation of earnings per share
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc. for the years ended December 31, 2015, 2014 and 2013 were calculated as follows:
 
 
2015
 
2014
(Restated)
 
2013
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.
 
$
(291.7
)
 
$
880.7

 
$
(866.1
)
Basic weighted-average number of common shares outstanding
 
342.7

 
335.4

 
321.0

Dilutive effect of stock options and RSUs
 
—

 
6.1

 
—

Diluted weighted-average number of common shares outstanding
 
342.7

 
341.5

 
321.0

 
 
 
 
 
 
 
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc.:
 
 
 
 
 
 
Basic
 
$
(0.85
)
 
$
2.63

 
$
(2.70
)
Diluted
 
$
(0.85
)
 
$
2.58

 
$
(2.70
)
Schedule of dilutive effect of stock options, RSUs and Convertible Notes on weighted-average number of common shares outstanding
The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
 
2015
 
2013
Basic weighted-average number of common shares outstanding
342.7

 
321.0

Dilutive effect of stock options and RSUs
6.1

 
6.5

Diluted weighted-average number of common shares outstanding
348.8

 
327.5